Skip to main content

Table 1 Demographic characteristics

From: Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

Number (%) of Subjects

(N=44)

Sex

 

Male

31 (70.5)

Female

13 (29.5)

Age (years)

 

Mean (SD)

57.8 (12.3)

Range

26-80

Age Category

 

<65

31 (70.5)

≥65

13 (29.5)

Race

 

White

41 (93.2)

Black

2 (4.5)

Asian

1 (2.3)

ECOG performance status

 

0

30 (68.2)

1

14 (31.8)

Current disease stage

 

IIIc

1 (2.3)

IV M1a

9 (20.5)

IV M1b

11 (25.0)

IV M1c

23 (52.3)

Measurable disease and adequate baseline assessment

 

Yes

37 (84.1)

No

4 (9.1)

Not reported

3 (6.8)

Number of involved disease sites

 

1

4 (9.1)

2

9 (20.5)

3

8 (18.2)

4

5 (11.4)

>4

18 (40.9)

ECOG = Eastern Co-operative Oncology Group